Compare Albertsons Companies Inc (ACI) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Crispr Therapeutics AG — how do they compare? Albertsons Companies Inc trades at $12.11 (market cap $5.95B), while Crispr Therapeutics AG trades at $53.9 (market cap $5.23B). The key difference: Albertsons Companies Inc and Crispr Therapeutics AG are close in size by market cap, and Albertsons Companies Inc pays a 5.55% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ACI | CRSP | |
|---|---|---|
Market Cap | $5.95B | $5.23B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $76.78 |
52-Week Low | $11.03 | $44.34 |
Enterprise Value | $21.35B | $3.65B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons Companies (ACI) trades at $12.135, showing minimal daily movement with a 0.04% gain. The stock faces bearish technical signals despite recent insider buying by the CEO and CFO. Fundamentals reveal declining profitability with net income margin at just 0.08% and falling revenue growth, though valuation metrics like P/S of 0.08 appear attractive. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple law firm investigations into potential securities violations.
ACI presents a high-risk opportunity with conflicting signals. While insider purchases and low valuation multiples suggest potential value, deteriorating margins, earnings misses, and legal scrutiny create significant headwinds. The stock's near-term trajectory depends on successful execution of the ACI Edge restructuring and digital initiatives to reverse profitability declines.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
